Close
Achema middle east
swop processing & packaging

Hilleman Laboratories Launches White Paper on Global Vaccine Equity

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Hilleman Laboratories is proud to announce the launch of the Hilleman Laboratories white paper entitled “Vaccines, Today and Tomorrow”.

The white paper is released on the back of the World Health Organisation (WHO) 2022 Global Vaccine Market Report released in the previous month, which captured lessons from the COVID-19 pandemic and highlighted opportunities to expand sustainable access to vaccines for populations around the world.

The pandemic has demonstrated inequitable distribution of vaccines is especially problematic in low- and middle-income countries (LMICs). For example, while the African region represents nearly 18% of the global population, it received just 3% of all COVID-19 vaccine doses in 2021. This phenomenon is not unique to COVID-19 vaccines; LMICs still have limited or delayed access to vaccines that high-income countries (HICs) have long supplied to the public such as the diphtheria, pertussis, tetanus third dose (DTP3), and Haemophilus influenzae type b (Hib) vaccines.

According to the white paper, the limited availability of vaccines is just one of the many factors for low vaccination rates in LMICs; other contributing factors include overstretched healthcare systems, limited cold chain logistics infrastructure, and challenges in securing multi-level community buy-in, and more needs to be done to strike a better balance between national interests, global public health objectives, and commercial incentives.

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »